Elbasvir-Grazoprevir +/- Ribavirin in HCV GT 4
Pooled Analysis

Source: Asselah T, et al. Liver Int. 2018;38:1583-91.

Elbasvir-Grazoprevir +/- RBV in HCV GT4
Pooled Analysis: Study Features

- **Design**: Pooled analysis of treatment naïve and treatment experienced adults with HCV genotype 4 who participated in phase 2 and 3 clinical trials involving treatment with elbasvir-grazoprevir for 12-16 weeks, with or without ribavirin.
- **Entry Criteria**
  - Chronic HCV genotype 4 (n = 155)
  - 18 years or older
  - Baseline HCV RNA ≥10,000 IU/mL
  - Treatment naïve & Treatment experienced (prior PEG-INF-based failure)
  - Persons with compensated cirrhosis permitted
  - Persons with HIV infection permitted
- **Primary End-Point**: SVR12

Source: Asselah T, et al. Liver Int. 2018;38:1583-91.

Elbasvir-Grazoprevir +/- RBV in HCV GT4
Pooled Analysis: Results in Treatment Naive



Abbreviations: EBR-GZR = elbasvir-grazoprevir; RBV = ribavirin

Source: Asselah T, et al. Liver Int. 2018;38:1583-91.

Elbasvir-Grazoprevir +/- RBV in HCV GT4
Pooled Analysis: Results in Treatment Experienced



Abbreviations: EBR-GZR = elbasvir-grazoprevir; RBV = ribavirin

Source: Asselah T, et al. Liver Int. 2018;38:1583-91.

Elbasvir-Grazoprevir +/- RBV in HCV GT4
Pooled Analysis: Conclusions

Conclusions: “The regimens of 12 weeks of elbasvir/grazoprevir without ribavirin, and 16 weeks of elbasvir/grazoprevir plus ribavirin, were efficacious in HCV GT4-infected treatment-naïve and treatment-experienced participants respectively. Baseline NS5A resistance-associated substitutions did not impact the efficacy of elbasvir/grazoprevir in GT4-infected participants.”

Source: Asselah T, et al. Liver Int. 2018;38:1583-91.

Acknowledgments

Hepatitis C Online is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.

HEPATITIS B ONLINE

HEPATITIS C ONLINE

IDEA INFECTIOUS DISEASES EDUCATION & ASSESSMENT